Literature DB >> 24696415

Increased expression of claudin-1 and claudin-7 in liver cirrhosis and hepatocellular carcinoma.

Ágnes Holczbauer1, Benedek Gyöngyösi, Gábor Lotz, Péter Törzsök, Pál Kaposi-Novák, Attila Szijártó, Péter Tátrai, Péter Kupcsulik, Zsuzsa Schaff, András Kiss.   

Abstract

Claudins have been reported to be differentially regulated in malignancies and implicated in the process of carcinogenesis and tumor progression. Claudin-1 has been described as key factor in the entry of hepatitis C virus (HCV) into hepatocytes and as promoter of epithelial-mesenchymal transition in liver cells. The objective of the current study was to characterize claudin expression in hepatocellular carcinoma (HCC) as well as HCC-surrounding and normal liver samples with respect to cirrhosis and HCV infection. Expression of claudin-1, -2, -3, -4, and -7 was measured by morphometric analysis of immunohistochemistry, and Western blotting in 30 HCCs with 30 corresponding non-tumorous tissues and 6 normal livers. Claudin-1 and -7 protein expression was found significantly elevated in cirrhosis when compared with non-cirrhotic liver. HCCs developed in cirrhotic livers showed even higher expression of claudin-1 contrary to decreased claudin-7 expression when compared with cirrhosis. With reference to HCV status, HCCs or surrounding livers of HCV-infected samples did not show significant alterations in claudin expression when compared with HCV-negative specimens. Cirrhotic transformation associates with elevated claudin-1 and -7 expressions in both non-tumorous liver and HCC. The fact that no significant differences in claudin expression were found regarding HCV-positivity in our sample set suggests that HCV infection alone does not induce a major increase in the total amount of its entry co-factor claudin-1. Increased expression of claudin-1 seems to be a consequence of cirrhotic transformation and might contribute to a more effective HCV entry and malignant transformation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24696415     DOI: 10.1007/s12253-013-9683-4

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  37 in total

1.  Dynamic changes in protein components of the tight junction during liver regeneration.

Authors:  Y Takaki; S Hirai; N Manabe; Y Izumi; T Hirose; M Nakaya; A Suzuki; K Mizuno; K Akimoto; S Tsukita; T Shuin; S Ohno
Journal:  Cell Tissue Res       Date:  2001-09       Impact factor: 5.249

2.  Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast.

Authors:  Scott L Kominsky; Pedram Argani; Dorian Korz; Ella Evron; Venu Raman; Elizabeth Garrett; Alan Rein; Guido Sauter; Olli-P Kallioniemi; Saraswati Sukumar
Journal:  Oncogene       Date:  2003-04-03       Impact factor: 9.867

3.  The expression of five different claudins in invasive breast carcinomas: comparison of pT1pN1 and pT1pN0 tumors.

Authors:  Anna-Mária Tokés; Janina Kulka; Sándor Paku; Miklós Máthé; Csilla Páska; Csaba Lódi; András Kiss; Zsuzsa Schaff
Journal:  Pathol Res Pract       Date:  2005       Impact factor: 3.250

4.  Tricellulin expression in normal and neoplastic human pancreas.

Authors:  Anna Korompay; Katalin Borka; Gábor Lotz; Aron Somorácz; Péter Törzsök; Boglárka Erdélyi-Belle; István Kenessey; Zsolt Baranyai; Fanni Zsoldos; Péter Kupcsulik; György Bodoky; Zsuzsa Schaff; András Kiss
Journal:  Histopathology       Date:  2012-03-06       Impact factor: 5.087

Review 5.  Histological grading and staging of chronic hepatitis.

Authors:  K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween
Journal:  J Hepatol       Date:  1995-06       Impact factor: 25.083

Review 6.  Primary liver cancer: worldwide incidence and trends.

Authors:  F Xavier Bosch; Josepa Ribes; Mireia Díaz; Ramon Cléries
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

7.  Hepatitis C virus receptors claudin-1 and occludin after liver transplantation and influence on early viral kinetics.

Authors:  Laura Mensa; Gonzalo Crespo; Matthew J Gastinger; Juraj Kabat; Sofía Pérez-del-Pulgar; Rosa Miquel; Suzanne U Emerson; Robert H Purcell; Xavier Forns
Journal:  Hepatology       Date:  2011-02-03       Impact factor: 17.425

8.  Increased expression of claudins in cervical squamous intraepithelial neoplasia and invasive carcinoma.

Authors:  Gábor Sobel; Csilla Páska; István Szabó; András Kiss; Anna Kádár; Zsuzsa Schaff
Journal:  Hum Pathol       Date:  2005-02       Impact factor: 3.466

9.  Claudin-1 acts through c-Abl-protein kinase Cdelta (PKCdelta) signaling and has a causal role in the acquisition of invasive capacity in human liver cells.

Authors:  Chang-Hwan Yoon; Min-Jung Kim; Myung-Jin Park; In-Chul Park; Sang-Gu Hwang; Sungkwan An; Yung-Hyun Choi; Gyesoon Yoon; Su-Jae Lee
Journal:  J Biol Chem       Date:  2009-11-06       Impact factor: 5.157

10.  Human hepatic stem cells from fetal and postnatal donors.

Authors:  Eva Schmelzer; Lili Zhang; Andrew Bruce; Eliane Wauthier; John Ludlow; Hsin-lei Yao; Nicholas Moss; Alaa Melhem; Randall McClelland; William Turner; Michael Kulik; Sonya Sherwood; Tommi Tallheden; Nancy Cheng; Mark E Furth; Lola M Reid
Journal:  J Exp Med       Date:  2007-07-30       Impact factor: 14.307

View more
  10 in total

1.  Claudin-9 enhances the metastatic potential of hepatocytes via Tyk2/Stat3 signaling.

Authors:  Hongyu Liu; Min Wang; Na Liang; Lianyue Guan
Journal:  Turk J Gastroenterol       Date:  2019-08       Impact factor: 1.852

Review 2.  Pathology of gallbladder carcinoma: current understanding and new perspectives.

Authors:  Munita Meenu Bal; Mukta Ramadwar; Kedar Deodhar; Shailesh Shrikhande
Journal:  Pathol Oncol Res       Date:  2015-01-25       Impact factor: 3.201

3.  Claudins-4 and -7 might be valuable markers to distinguish hepatocellular carcinoma from cholangiocarcinoma.

Authors:  Yusuke Ono; Yutaro Hiratsuka; Masaki Murata; Akira Takasawa; Rieko Fukuda; Masanori Nojima; Satoshi Tanaka; Makoto Osanai; Koichi Hirata; Norimasa Sawada
Journal:  Virchows Arch       Date:  2016-07-21       Impact factor: 4.064

Review 4.  Tight Junction Proteins and the Biology of Hepatobiliary Disease.

Authors:  Natascha Roehlen; Armando Andres Roca Suarez; Houssein El Saghire; Antonio Saviano; Catherine Schuster; Joachim Lupberger; Thomas F Baumert
Journal:  Int J Mol Sci       Date:  2020-01-28       Impact factor: 5.923

Review 5.  Immunomodulation by probiotics and prebiotics in hepatocellular carcinoma.

Authors:  Edda Russo; Camila Fiorindi; Francesco Giudici; Amedeo Amedei
Journal:  World J Hepatol       Date:  2022-02-27

Review 6.  Tight junction proteins in gastrointestinal and liver disease.

Authors:  Mirjam B Zeisel; Punita Dhawan; Thomas F Baumert
Journal:  Gut       Date:  2018-10-08       Impact factor: 31.793

7.  Palmitoylated claudin7 captured in glycolipid-enriched membrane microdomains promotes metastasis via associated transmembrane and cytosolic molecules.

Authors:  Florian Thuma; Sarah Heiler; Martina Schnölzer; Margot Zöller
Journal:  Oncotarget       Date:  2016-05-24

8.  Disruption of Claudin-1 Expression by miRNA-182 Alters the Susceptibility to Viral Infectivity in HCV Cell Models.

Authors:  Sarah E Riad; Dalia S Elhelw; Heba Shawer; Nada El-Ekiaby; Ayman Salah; Abdelrahman Zekri; Gamal Esmat; Asma Amleh; Ahmed I Abdelaziz
Journal:  Front Genet       Date:  2018-03-20       Impact factor: 4.599

Review 9.  Emerging clinical significance of claudin-7 in colorectal cancer: a review.

Authors:  Kun Wang; Chang Xu; Wenjing Li; Lei Ding
Journal:  Cancer Manag Res       Date:  2018-09-20       Impact factor: 3.989

10.  Role of tight junction-associated MARVEL protein marvelD3 in migration and epithelial-mesenchymal transition of hepatocellular carcinoma.

Authors:  Yanmeng Li; Teng Li; Donghu Zhou; Jia Wei; Zhenkun Li; Xiaojin Li; Siyu Jia; Qin Ouyang; Saiping Qi; Zhibin Chen; Bei Zhang; Jing Yu; Jidong Jia; Anjian Xu; Jian Huang
Journal:  Cell Adh Migr       Date:  2021-12       Impact factor: 3.405

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.